Skip to main content
SpringerLink
Log in

Chemoradiotherapy and surgery for T4 esophageal cancer in Japan

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness. The most effective treatment modality for esophageal cancer, particularly T4 esophageal cancer, is chemoradiotherapy (CRT). Some T4 patients show long-term survival after receiving CRT, suggesting that even T4 esophageal cancer can be cured with this modality. Although surgery is performed after CRT in some T4 cases, its prognostic benefit is controversial. In this paper, we review the status of CRT and conversion surgery as well as the development of new regimens and discuss the future prospects of CRT in the treatment of T4 esophageal cancer in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shimada H, Shiratori T, Okazumi S, et al. Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg. 2008;206:48–56.

    Article  PubMed  Google Scholar 

  2. Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive registry of esophageal cancer in Japan, 2006. Esophagus. 2013. doi:10.1007/s10388-013-0393-5.

    Google Scholar 

  3. Chak A, Canto M, Gerdes H, et al. Prognosis of esophageal cancers preoperatively staged to be locally invasive (T4) by endoscopic ultrasound (EUS): a multicenter retrospective cohort study. Gastrointest Endosc. 1995;42:501–6.

    Article  CAS  PubMed  Google Scholar 

  4. Akutsu Y, Kono T, Uesato M, et al. Is the outcome of a salvage surgery for t4 thoracic esophageal squamous cell carcinoma really poor? World J Surg. 2014;38:2891–7

    Article  PubMed  Google Scholar 

  5. Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–8.

    Article  PubMed  Google Scholar 

  6. Pimiento JM, Weber J, Hoffe SE, et al. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013;20:2706–12.

    Article  PubMed  Google Scholar 

  7. Seto Y, Chin K, Gomi K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007;98:937–42.

    Article  CAS  PubMed  Google Scholar 

  8. Kuroda J, Yoshida M, Kitajima M, et al. Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma. J Gastroenterol Hepatol. 2012;27(Suppl 3):88–94.

    Article  PubMed  Google Scholar 

  9. Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70:25–32.

    Article  CAS  PubMed  Google Scholar 

  10. Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17:221–8.

    Article  PubMed  Google Scholar 

  12. Japan Esophageal Society. Guidelines for diagnosis and treatment of carcinoma of the esophagus. Tokyo: Kanehara; 2012.

    Google Scholar 

  13. Ohtsu A, Yoshida S, Boku N, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 1995;25:261–6.

    CAS  PubMed  Google Scholar 

  14. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.

    CAS  PubMed  Google Scholar 

  15. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134–9.

    Article  CAS  PubMed  Google Scholar 

  16. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.

    Article  PubMed  Google Scholar 

  17. Shinoda M, Ando N, Kato H, et al. A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). J Clin Oncol. 2010;28(No 15_suppl):Abstract 4053.

    Google Scholar 

  18. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.

    Article  CAS  PubMed  Google Scholar 

  19. Van Raemdonck D, Van Cutsem E, Menten J, Ectors N, Coosemans W, De Leyn P, Lerut T. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997;11:828–37.

    Article  PubMed  Google Scholar 

  20. Noguchi T, Moriyama H, Wada S, Takeno S, Wakisaka M, Mori H, Uchida Y. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus. 2003;16:94–8.

    Article  CAS  PubMed  Google Scholar 

  21. Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30 (discussion 30–1).

    Article  PubMed  Google Scholar 

  22. Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.

    Article  CAS  PubMed  Google Scholar 

  23. Fujita H, Sueyoshi S, Tanaka T, et al. Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol. 2005;90:209–19.

    Article  PubMed  Google Scholar 

  24. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.

    Article  CAS  PubMed  Google Scholar 

  25. Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009;29:403–21.

    Article  PubMed  Google Scholar 

  26. Karimata H, Shimoji H, Nishimaki T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg Today. 2014.

  27. Wayman J, Chakraverty S, Griffin SM, Doyle GJ, Keir MJ, Simpson W. Evaluation of local invasion by oesophageal carcinoma—a prospective study of prone computed tomography scanning. Postgrad Med J. 2001;77:181–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Ito B, Niwa Y, Ando N, et al. Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography. Eur J Radiol. 2005;54:377–82.

    Article  PubMed  Google Scholar 

  29. Yamada I, Izumi Y, Kawano T, Yoshino N, Tetsumura A, Kumagai J, Shibuya H. Esophageal carcinoma: evaluation with high-resolution three-dimensional constructive interference in steady state MR imaging in vitro. J Magn Reson Imaging. 2006;24:1326–32.

    Article  PubMed  Google Scholar 

  30. Wakamatsu T, Tsushima K, Yasuo M, et al. Usefulness of preoperative endobronchial ultrasound for airway invasion around the trachea: esophageal cancer and thyroid cancer. Respiration. 2006;73:651–7.

    Article  PubMed  Google Scholar 

  31. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.

    Article  CAS  PubMed  Google Scholar 

  32. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.

    Article  CAS  PubMed  Google Scholar 

  33. Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31:3535–41.

    CAS  PubMed  Google Scholar 

  34. Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105:1189–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106:441–7.

    Article  PubMed  Google Scholar 

  36. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease and oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.

    Article  CAS  PubMed  Google Scholar 

  37. Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014.

  38. Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18:2946–51.

    Article  PubMed  Google Scholar 

  39. Yusup G, Akutsu Y, Mutallip M, et al. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int J Oncol. 2014;44:1146–52.

    CAS  PubMed  Google Scholar 

  40. Yoneda M, Fujiwara H, Furutani A, et al. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. Anticancer Res. 2013;33:2699–705.

    CAS  PubMed  Google Scholar 

  41. Makuuchi Y, Honda K, Osaka Y, et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104:1045–51.

    Article  CAS  PubMed  Google Scholar 

  42. Zhang JX, Tong ZT, Yang L, et al. PITX2: a promising predictive biomarker of patients’ prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer. 2013;132:2567–77.

    Article  CAS  PubMed  Google Scholar 

  43. Imanishi S, Shuto K, Aoyagi T, Kono T, Saito H, Matsubara H. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg. 2013;30:240–8.

    Article  CAS  PubMed  Google Scholar 

  44. Akutsu Y, Yasuda S, Nagata M, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012;105:750–5.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

There are no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuoku, Chiba, 260-8670, Japan

    Yasunori Akutsu & Hisahiro Matsubara

Authors
  1. Yasunori Akutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisahiro Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasunori Akutsu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akutsu, Y., Matsubara, H. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today 45, 1360–1365 (2015). https://doi.org/10.1007/s00595-015-1116-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-015-1116-4

Keywords

Search

Navigation